Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 15;12(4):408. doi: 10.1038/s41419-021-03681-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Co-immunoprecipitation (Co-IP) detected whether PFKM with NOS1 could bind in SKOV3-OE-NOS1 cells by using PFKM monoclonal antibody (upon); PFKM, one proposed NOS1 binding partner, display a class II PDZ domain-binding motif at its C termini (down). b Co-IP detected whether NOS1 with PFKL, PFKP, and PFKM could bind in SKOV3-OE-NOS1 cells by using NOS1 monoclonal antibody. c Western blot results showed that PDZ domain of GST-tagged could bind to PFKM by GST pull-down assay. d Enzyme kinetics assay displayed the K_m (the concentration of F-6-P required to reach half-maximal activation) decreased significantly and the V_max (maximum velocity) increased significantly in the SKOV3-OE-NOS1 cells (K_m = 0.591 and 0.692, V_max = 8.33 and 2.6 μM/min for OE-NOS1 and control cells respectively) (***P < 0.001, one-way ANOVA). e Western blotting by non-reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) displayed the tetramer and dimer contents of PFKM in OE-NOS1 and control SKOV3 cells. f The tetramer and dimer contents of PFKM in SKOV3 and OVCAR3 cells treated with GSNO (1 mM) or PBS for 30 min respectively. g The activity of PFKM under different concentrations of citrate (left), Lactate (middle) and ATP (right) in SKOV3 vs. NOS1-KO cells and SKOV3-OE-NOS1 vs. control cells. h Boxplots correlating the stage of tumors and the mRNA expression levels of tumor glycolytic genes PFKM are shown in ovary cancer samples (GSE51373). (**p < 0.01, Student’s t-test). i Kaplan–Meier analyzed for the overall survival time between PFKM high or low expressed patients.